These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 10837192

  • 1. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance.
    Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW.
    J Infect Dis; 2000 Jun; 181(6):2055-8. PubMed ID: 10837192
    [Abstract] [Full Text] [Related]

  • 2. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation.
    Chen Y, Scieux C, Garrait V, Socié G, Rocha V, Molina JM, Thouvenot D, Morfin F, Hocqueloux L, Garderet L, Espérou H, Sélimi F, Devergie A, Leleu G, Aymard M, Morinet F, Gluckman E, Ribaud P.
    Clin Infect Dis; 2000 Oct; 31(4):927-35. PubMed ID: 11049772
    [Abstract] [Full Text] [Related]

  • 3. Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution.
    Frangoul H, Wills M, Crossno C, Engel M, Domm J.
    Pediatr Transplant; 2007 Dec; 11(8):942-4. PubMed ID: 17976133
    [Abstract] [Full Text] [Related]

  • 4. Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients.
    Stránská R, van Loon AM, Polman M, Beersma MF, Bredius RG, Lankester AC, Meijer E, Schuurman R.
    Antivir Ther; 2004 Aug; 9(4):565-75. PubMed ID: 15456088
    [Abstract] [Full Text] [Related]

  • 5. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [Abstract] [Full Text] [Related]

  • 6. Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study.
    Ariza-Heredia EJ, Chemaly RF, Shahani LR, Jang Y, Champlin RE, Mulanovich VE.
    Transpl Int; 2018 Jun; 31(6):639-648. PubMed ID: 29464765
    [Abstract] [Full Text] [Related]

  • 7. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V, Kansoy S, Küpesiz A, Aksoylar S, Kantar M, Yeşilipek A.
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [Abstract] [Full Text] [Related]

  • 8. Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT.
    Verdonck LF, Cornelissen JJ, Smit J, Lepoutre J, de Gast GC, Dekker AW, Rozenberg-Arska M.
    Bone Marrow Transplant; 1993 Feb; 11(2):177-9. PubMed ID: 8382096
    [Abstract] [Full Text] [Related]

  • 9. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders.
    Kim DH, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J, Lipton J.
    Transpl Infect Dis; 2008 Apr; 10(2):90-8. PubMed ID: 17605742
    [Abstract] [Full Text] [Related]

  • 10. Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Venard V, Dauendorffer JN, Carret AS, Corsaro D, Edert D, Bordigoni P, Le Faou A.
    Pathol Biol (Paris); 2001 Sep; 49(7):553-8. PubMed ID: 11642018
    [Abstract] [Full Text] [Related]

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.
    Arnulf B, Chebbi F, Lefrere F, Ait Arkoub Z, Varet B, Fillet AM.
    Bone Marrow Transplant; 2001 Oct; 28(8):799-801. PubMed ID: 11781635
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H, Iida H, Shimokawa T, Kohno A, Mizuta S, Maruyama F, Wakita A, Kitaori K, Yano K, Hamaguchi M, Hamajima N, Morishima Y, Kodera Y, Sao H, Morishita Y.
    Bone Marrow Transplant; 2003 Oct; 32(8):801-7. PubMed ID: 14520425
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation.
    Dignani MC, Mykietiuk A, Michelet M, Intile D, Mammana L, Desmery P, Milone G, Pavlovsky S.
    Bone Marrow Transplant; 2002 Feb; 29(3):263-7. PubMed ID: 11859400
    [Abstract] [Full Text] [Related]

  • 19. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS.
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [Abstract] [Full Text] [Related]

  • 20. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.